BioClin Therapeutics is a San Leandro, CA–based clinical-stage drug development company developing B-701, an anti-FGFR3 monoclonal antibody for metastatic bladder cancer (metastatic urothelial carcinoma). Its lead candidate B-701 is being evaluated as monotherapy and in combination with standard-of-care chemotherapy and with pembrolizumab, an immune checkpoint inhibitor. The company will use newly raised funds to advance B-701 and to broaden its clinical development activities. BioClin is led by CEO Stephen Lau. Financially, the company raised an additional $20M in the reported financing, bringing its Series B to $50M and totaling $79M raised since founding. Ongoing clinical studies include B-701 monotherapy and B-701 in combination regimens for patients with metastatic bladder cancer. BioClin Therapeutics is a privately-held clinical-stage drug development company developing a first-in-class anti-FGFR3 human monoclonal antibody, B-701. B-701 is being evaluated for metastatic bladder cancer (metastatic urothelial carcinoma) in a Phase 1b/2 study both as monotherapy and in combination with docetaxel, with cohorts for patients with FGFR3 mutation or fusion. A second Phase 1b/2 study will evaluate B-701 in combination with atezolizumab in patients with overexpressed FGFR3 as well as those with FGFR3 mutation or fusion. B-701 is also being tested in an ongoing investigator-sponsored study in combination with pembrolizumab in mUC patients. The company plans to use new financing to expand the docetaxel combination trial and initiate the atezolizumab combination trial. BioClin is based in San Ramon, Calif., and has raised a total of $59 million since founding.

Total raised

$80M

Funding rounds

2

Latest round

Series B

Latest activity

May 2018